BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abon Announces CLOLAR® Patent Challenge


7/31/2012 10:47:37 AM

NORTHVALE, N.J., July 31, 2012 /PRNewswire/ -- Abon Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced that it has filed an Abbreviated New Drug Application (ANDA), with a paragraph IV certification, with the U.S. Food and Drug Administration (FDA) seeking approval to market its Clofarabine Injection, 1 mg/ml. Abon's Clofarabine Injection is a generic equivalent of Genzyme's CLOLAR® Injection. CLOLAR® injection is a prescription medicine indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Genzyme filed suit against Abon on July 27, 2012, in the United States District Court for the District of New Jersey seeking to prevent Abon from commercializing its product prior to the expiration of U.S. Patent No. 5,661,136.

Based on available information, Abon believes it may be the "first applicant" to file an ANDA for the generic version of CLOLAR® Injection and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

Total US sales for the twelve month period ending in June 2012 were approximately $77.5 million, according to IMS Health.

"This filing is an important milestone for Abon. It establishes our capability to expedite development of generic products facing significant barriers to entry," said Dr. Salah U. Ahmed, President, CEO and founder of Abon Pharmaceuticals, LLC. While several ANDAs for products developed by Abon have been filed with the FDA by its strategic partners, the Clofarabine Injection ANDA is the first to be filed and owned by Abon.

About Abon Pharmaceuticals, LLC

Abon Pharmaceuticals, LLC is a specialty pharmaceutical company that emphasizes science and technology in the development of generic and proprietary products that have challenging formulation barriers. Abon has filed multiple patent applications for drug delivery technologies. The founders and employees of Abon have extensive experience in the pharmaceutical field, with notable successes in developing and bringing many first entry generic products to market. Prior to founding Abon in 2009, Salah U. Ahmed, PhD, was the CSO and Executive VP of Global Research and Development at Barr Laboratories, Inc., and Bruce Downey Esq., another of the founders, was the Chairman of the Board and CEO of Barr Pharmaceuticals, Inc.

For press release and other company information, please visit Abon Pharmaceutical, LLCs' website at http://www.abonpharma.com.

SOURCE Abon Pharmaceuticals, LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES